Giant-Cell Arteritis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Giant-Cell Arteritis pipeline constitutes 6+ key companies continuously working towards developing 6+ Giant-Cell Arteritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Giant-Cell Arteritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Giant-Cell Arteritis Market.

The Giant-Cell Arteritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Giant-Cell Arteritis Pipeline Report:
• Giant-Cell Arteritis Companies across the globe are diligently working toward developing novel Giant-Cell Arteritis treatment therapies with a considerable amount of success over the years.
• Giant-Cell Arteritis companies working in the treatment market are Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddy's Laboratories and others, are developing therapies for the Giant-Cell Arteritis treatment
• Emerging Giant-Cell Arteritis therapies such as Secukinumab, Upadacitinib, and others are expected to have a significant impact on the Giant-Cell Arteritis market in the coming years.
• On November 2024, Novartis announced results of a Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of Subcutaneously Administered Secukinumab in Patients With New-onset of Giant Cell Arteritis (GCA) Who Are in Clinical Remission and Eligible for Treatment With Glucocorticoid-monotherapy
• On Feb 2024, AbbVie announced results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis: SELECT-GCA

Giant-Cell Arteritis Overview
Giant-Cell Arteritis (GCA), also known as temporal arteritis, is a chronic inflammatory disease affecting large- and medium-sized arteries, predominantly the temporal arteries. It is the most common systemic vasculitis in adults over 50, with a higher prevalence in women and individuals of Northern European descent.
The inflammation in Giant-Cell Arteritis leads to the narrowing or blockage of blood vessels, reducing blood flow. Symptoms typically include headache, scalp tenderness, jaw claudication (pain while chewing), fatigue, fever, and vision disturbances. In severe cases, untreated GCA can cause permanent vision loss or stroke.
Giant-Cell Arteritis Diagnosis is based on clinical evaluation, elevated inflammatory markers (such as ESR and CRP), and confirmation via temporal artery biopsy or advanced imaging modalities like ultrasound, MRI, or PET scans.
Giant-Cell Arteritis Treatment involves high-dose corticosteroids to rapidly reduce inflammation and prevent complications, often initiated immediately upon suspicion of Giant-Cell Arteritis. Immunosuppressive agents like methotrexate or biologics such as tocilizumab may be used as steroid-sparing therapies.
Early detection and management are critical to preventing irreversible complications. Regular follow-ups are essential to monitor disease activity and mitigate long-term side effects of treatment, such as osteoporosis or diabetes, emphasizing the need for a multidisciplinary approach in Giant-Cell Arteritis care.

Get a Free Sample PDF Report to know more about Giant-Cell Arteritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Giant-Cell Arteritis Route of Administration
Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Giant-Cell Arteritis Molecule Type
Giant-Cell Arteritis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Giant-Cell Arteritis Pipeline Therapeutics Assessment
• Giant-Cell Arteritis Assessment by Product Type
• Giant-Cell Arteritis By Stage and Product Type
• Giant-Cell Arteritis Assessment by Route of Administration
• Giant-Cell Arteritis By Stage and Route of Administration
• Giant-Cell Arteritis Assessment by Molecule Type
• Giant-Cell Arteritis by Stage and Molecule Type

DelveInsight's Giant-Cell Arteritis Report covers around 6+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Giant-Cell Arteritis product details are provided in the report. Download the Giant-Cell Arteritis pipeline report to learn more about the emerging Giant-Cell Arteritis therapies- https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Giant-Cell Arteritis Pipeline Analysis:
The Giant-Cell Arteritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Giant-Cell Arteritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Giant-Cell Arteritis Treatment.
• Giant-Cell Arteritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Giant-Cell Arteritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Giant-Cell Arteritis market.

Download Sample PDF Report to know more about Giant-Cell Arteritis drugs and therapies- https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Giant-Cell Arteritis Pipeline Drug Insight
• Coverage: Global
• Key Giant-Cell Arteritis Companies: Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddy's Laboratories and others.
• Key Giant-Cell Arteritis Therapies: Secukinumab, Upadacitinib, and others.
• Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis current marketed and Giant-Cell Arteritis emerging therapies
• Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers

Request for Sample PDF Report for Giant-Cell Arteritis Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Giant-Cell Arteritis Report Introduction
2. Giant-Cell Arteritis Executive Summary
3. Giant-Cell Arteritis Overview:
4. Giant-Cell Arteritis- Analytical Perspective In-depth Commercial Assessment
5. Giant-Cell Arteritis Pipeline Therapeutics
6. Giant-Cell Arteritis Late Stage Products (Phase II/III)
7. Giant-Cell Arteritis Mid Stage Products (Phase II)
8. Giant-Cell Arteritis Early Stage Products (Phase I)
9. Giant-Cell Arteritis Preclinical Stage Products
10. Giant-Cell Arteritis Therapeutics Assessment
11. Giant-Cell Arteritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Giant-Cell Arteritis Companies
14. Giant-Cell Arteritis Key Products
15. Giant-Cell Arteritis Unmet Needs
16 . Giant-Cell Arteritis Market Drivers and Barriers
17. Giant-Cell Arteritis Future Perspectives and Conclusion
18. Giant-Cell Arteritis Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Hyperinsulinemic Hypoglycemia Market: https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market
• Nmibc Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Parkinsons Disease Related Dementia Market: https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Refractory Angina Market: https://www.delveinsight.com/report-store/refractory-angina-market
• Sanfilippo Syndrome Market: https://www.delveinsight.com/report-store/sanfilippo-syndrome-type-a-mps-iiia-market
• Scleroderma Market: https://www.delveinsight.com/report-store/systemic-sclerosis-market
• Thrombocytopenia Market: https://www.delveinsight.com/report-store/thrombocytopenia-market
• Treatment Resistant Depression Market: https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market
• Turner Syndrome Market: https://www.delveinsight.com/report-store/turner-syndrome-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.